BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33636207)

  • 1. Cross-reactivity of NRASQ61R antibody in a subset of Spitz nevi with 11p gain: a potential confounding factor in the era of pathway-based diagnostic approach.
    Parra O; Lefferts JA; Tafe LJ; Gru AA; Linos K
    Hum Pathol; 2021 Jun; 112():35-47. PubMed ID: 33636207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.
    Reagh J; Bullock M; Andrici J; Turchini J; Sioson L; Clarkson A; Watson N; Sheen A; Lim G; Delbridge L; Sidhu S; Sywak M; Aniss A; Shepherd P; Ng D; Oei P; Field M; Learoyd D; Robinson BG; Clifton-Bligh RJ; Gill AJ
    Am J Surg Pathol; 2017 Jan; 41(1):75-81. PubMed ID: 27635947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spitz melanoma is a distinct subset of spitzoid melanoma.
    Raghavan SS; Peternel S; Mully TW; North JP; Pincus LB; LeBoit PE; McCalmont TH; Bastian BC; Yeh I
    Mod Pathol; 2020 Jun; 33(6):1122-1134. PubMed ID: 31900433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
    van Dijk MC; Bernsen MR; Ruiter DJ
    Am J Surg Pathol; 2005 Sep; 29(9):1145-51. PubMed ID: 16096402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and NRAS mutations in spitzoid melanocytic lesions.
    Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
    Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after BRAF and NRAS mutation characterisation: a single institution experience.
    Moysset I; Castrejon N; Garcia-Herrera A; Castillo P; Marginet M; Teixido C; Podlipnik S; Albero-Gonzalez R; Montironi C; Navarro J; Rovira C; Puig S; Carrera C; Alos L
    Histopathology; 2024 Jun; 84(7):1154-1166. PubMed ID: 38409889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
    Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
    J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
    Quan VL; Zhang B; Zhang Y; Mohan LS; Shi K; Wagner A; Kruse L; Taxter T; Beaubier N; White K; Zou L; Gerami P
    J Invest Dermatol; 2020 Aug; 140(8):1599-1608. PubMed ID: 32004563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study.
    Garrido-Ruiz MC; Requena L; Ortiz P; Pérez-Gómez B; Alonso SR; Peralto JL
    Mod Pathol; 2010 Sep; 23(9):1215-24. PubMed ID: 20543820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME immunohistochemistry of spitzoid neoplasms.
    Koh SS; Lau SK; Scapa JV; Cassarino DS
    J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
    Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
    Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
    Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
    Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features.
    van Engen-van Grunsven AC; van Dijk MC; Ruiter DJ; Klaasen A; Mooi WJ; Blokx WA
    Am J Surg Pathol; 2010 Oct; 34(10):1436-41. PubMed ID: 20871217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
    Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
    Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
    Zaremba A; Jansen P; Murali R; Mayakonda A; Riedel A; Philip M; Rose C; Schaller J; Müller H; Kutzner H; Möller I; Stadtler N; Kretz J; Sucker A; Bankfalvi A; Livingstone E; Zimmer L; Horn S; Paschen A; Plass C; Schadendorf D; Hadaschik E; Lutsik P; Griewank K
    Int J Cancer; 2022 Nov; 151(9):1542-1554. PubMed ID: 35737508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report.
    Vachtenheim J; Kodet R; Fischer O; Kolek V; Strizova Z; Ozaniak A; Simonek J; Stolz A; Pozniak J; Kolarik J; Svorcova M; Vachtenheim J; Lischke R
    Diagn Pathol; 2020 Oct; 15(1):132. PubMed ID: 33100226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the Spectrum of Microscopic and Cytogenetic Findings Associated With Spitz Tumors With 11p Gains.
    Lezcano CM; Yeh I; Eslamdoost N; Fang Y; LeBoit PE; McCalmont TH; Moy AP; Zhang Y; Busam KJ
    Am J Surg Pathol; 2021 Feb; 45(2):277-285. PubMed ID: 33428338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas.
    Lazova R; Pornputtapong N; Halaban R; Bosenberg M; Bai Y; Chai H; Krauthammer M
    Mod Pathol; 2017 May; 30(5):640-649. PubMed ID: 28186096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
    Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
    Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.